1. Home
  2. PTMN vs SAVA Comparison

PTMN vs SAVA Comparison

Compare PTMN & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PTMN
  • SAVA
  • Stock Information
  • Founded
  • PTMN 2006
  • SAVA 1998
  • Country
  • PTMN United States
  • SAVA United States
  • Employees
  • PTMN N/A
  • SAVA N/A
  • Industry
  • PTMN Finance: Consumer Services
  • SAVA Biotechnology: Pharmaceutical Preparations
  • Sector
  • PTMN Finance
  • SAVA Health Care
  • Exchange
  • PTMN Nasdaq
  • SAVA Nasdaq
  • Market Cap
  • PTMN 142.6M
  • SAVA 137.2M
  • IPO Year
  • PTMN N/A
  • SAVA N/A
  • Fundamental
  • Price
  • PTMN $14.15
  • SAVA $1.50
  • Analyst Decision
  • PTMN Hold
  • SAVA Buy
  • Analyst Count
  • PTMN 1
  • SAVA 3
  • Target Price
  • PTMN $16.00
  • SAVA $54.50
  • AVG Volume (30 Days)
  • PTMN 54.6K
  • SAVA 2.3M
  • Earning Date
  • PTMN 03-13-2025
  • SAVA 03-03-2025
  • Dividend Yield
  • PTMN 14.97%
  • SAVA N/A
  • EPS Growth
  • PTMN N/A
  • SAVA N/A
  • EPS
  • PTMN N/A
  • SAVA N/A
  • Revenue
  • PTMN $62,432,000.00
  • SAVA N/A
  • Revenue This Year
  • PTMN $6.34
  • SAVA N/A
  • Revenue Next Year
  • PTMN N/A
  • SAVA N/A
  • P/E Ratio
  • PTMN N/A
  • SAVA N/A
  • Revenue Growth
  • PTMN N/A
  • SAVA N/A
  • 52 Week Low
  • PTMN $14.15
  • SAVA $1.50
  • 52 Week High
  • PTMN $20.84
  • SAVA $42.20
  • Technical
  • Relative Strength Index (RSI)
  • PTMN 17.80
  • SAVA 24.92
  • Support Level
  • PTMN $14.30
  • SAVA $1.63
  • Resistance Level
  • PTMN $15.69
  • SAVA $1.79
  • Average True Range (ATR)
  • PTMN 0.43
  • SAVA 0.20
  • MACD
  • PTMN -0.16
  • SAVA -0.13
  • Stochastic Oscillator
  • PTMN 1.83
  • SAVA 0.00

About PTMN Portman Ridge Finance Corporation

Portman Ridge Finance Corp Inc is a non-diversified closed-end investment company. The company originates, structures, and invests in secured term loans, bonds or notes, and mezzanine debt primarily in privately-held middle market companies but may also invest in other investments such as loans to publicly traded companies, high-yield bonds, and distressed debt securities. The company's investment objective in the Debt securities portfolio is to generate current income and, to a lesser extent, capital appreciation from the investments in senior secured term loans, mezzanine debt, and selected equity investments in privately-held middle market companies.

About SAVA Cassava Sciences Inc.

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.

Share on Social Networks: